KR102677601B1 - Antimicrobial composition comprising the kenaf seed extract of jang-dae cultivar - Google Patents
Antimicrobial composition comprising the kenaf seed extract of jang-dae cultivar Download PDFInfo
- Publication number
- KR102677601B1 KR102677601B1 KR1020220031067A KR20220031067A KR102677601B1 KR 102677601 B1 KR102677601 B1 KR 102677601B1 KR 1020220031067 A KR1020220031067 A KR 1020220031067A KR 20220031067 A KR20220031067 A KR 20220031067A KR 102677601 B1 KR102677601 B1 KR 102677601B1
- Authority
- KR
- South Korea
- Prior art keywords
- kenaf
- antibacterial
- seed extract
- variety
- present
- Prior art date
Links
- 240000000797 Hibiscus cannabinus Species 0.000 title claims abstract description 107
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 239000000284 extract Substances 0.000 title abstract description 56
- 230000000845 anti-microbial effect Effects 0.000 title 1
- 241001465754 Metazoa Species 0.000 claims abstract description 20
- 239000000654 additive Substances 0.000 claims abstract description 20
- 235000015928 Hibiscus cannabinus Nutrition 0.000 claims abstract description 16
- 239000002537 cosmetic Substances 0.000 claims abstract description 16
- 239000003599 detergent Substances 0.000 claims abstract description 15
- 230000036541 health Effects 0.000 claims abstract description 15
- 235000013376 functional food Nutrition 0.000 claims abstract description 13
- 239000012459 cleaning agent Substances 0.000 claims abstract description 11
- 241000196324 Embryophyta Species 0.000 claims description 10
- 239000000469 ethanolic extract Substances 0.000 claims description 6
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 239000000490 cosmetic additive Substances 0.000 claims description 3
- 239000012871 anti-fungal composition Substances 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 67
- 235000013305 food Nutrition 0.000 abstract description 22
- 239000004480 active ingredient Substances 0.000 abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 12
- 241000192125 Firmicutes Species 0.000 abstract description 8
- 239000000843 powder Substances 0.000 abstract description 6
- 244000144972 livestock Species 0.000 abstract description 4
- 239000003826 tablet Substances 0.000 abstract description 4
- 239000006071 cream Substances 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 3
- 210000002381 plasma Anatomy 0.000 abstract description 3
- 230000002378 acidificating effect Effects 0.000 abstract description 2
- 239000006187 pill Substances 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 description 15
- 239000003242 anti bacterial agent Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- -1 kaempferol compound Chemical class 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 239000000049 pigment Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000233866 Fungi Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229930003935 flavonoid Natural products 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- 238000000227 grinding Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 5
- 230000000843 anti-fungal effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 4
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 4
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000010208 anthocyanin Nutrition 0.000 description 4
- 229930002877 anthocyanin Natural products 0.000 description 4
- 239000004410 anthocyanin Substances 0.000 description 4
- 150000004636 anthocyanins Chemical class 0.000 description 4
- 235000009120 camo Nutrition 0.000 description 4
- 235000005607 chanvre indien Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000011487 hemp Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 241000238557 Decapoda Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000286209 Phasianidae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- 241000258955 Echinodermata Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- 241000237852 Mollusca Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 241000269908 Platichthys flesus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 235000008777 kaempferol Nutrition 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempherol Natural products C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 240000000491 Corchorus aestuans Species 0.000 description 1
- 235000011777 Corchorus aestuans Nutrition 0.000 description 1
- 235000010862 Corchorus capsularis Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001282110 Pagrus major Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 240000000697 Pinguicula vulgaris Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000751182 Staphylococcus epidermidis ATCC 12228 Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003048 aphrodisiac agent Substances 0.000 description 1
- 230000002509 aphrodisiac effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004851 dishwashing Methods 0.000 description 1
- 230000024346 drought recovery Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000012770 industrial material Substances 0.000 description 1
- 238000007603 infrared drying Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- LGZXYFMMLRYXLK-UHFFFAOYSA-N mercury(2+);sulfide Chemical compound [S-2].[Hg+2] LGZXYFMMLRYXLK-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007226 seed germination Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/382—Vegetable products, e.g. soya meal, wood flour, sawdust
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Wood Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Medical Informatics (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Animal Husbandry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 케나프(Kenaf, Hibiscus cannabinus L.) 종자 추출물을 유효성분으로 포함하는 항균 조성물에 관한 것으로서, 보다 구체적으로는, 보다 구체적으로는, 국내 재배 및 채종이 가능한 케나프 신품종 장대의 종자 추출물을 유효성분으로 포함하는 그람 양성 세균에 대한 항균 조성물에 관한 것이다. 본 발명의 광범위 항균 조성물의 유효성분으로서의 대한민국 품종보호권 등록번호 제4560호인 장대 품종의 케나프(Kenaf, Hibiscus cannabinus L.) 종자 추출물은 우수한 항균 활성을 나타내어, 항균용 약학 조성물, 건강 기능 식품, 화장료 조성물, 동물 사료 조성물, 식품, 화장품 또는 동물 사료용 첨가물, 각종 세정제 및 각종 청결제 등의 용도로 사용할 수 있는 뛰어난 효과가 있다. 뿐만 아니라, 본 발명의 대한민국 품종보호권 등록번호 제4560호인 장대 품종의 케나프(Kenaf, Hibiscus cannabinus L.) 종자 추출물은 열 안정성이 우수하고, pH 2의 산성조건 및 혈장 내에서도 활성의 손실이 나타나지 않아, 액상, 크림, 분말, 환, 정 등의 다양한 형태로 손쉽게 가공될 수 있어 제약 산업, 식품 산업, 축산업, 보건 산업 및 화장품 산업상 매우 유용하게 이용될 수 있다.The present invention relates to an antibacterial composition containing kenaf ( Hibiscus cannabinus L.) seed extract as an active ingredient, and more specifically, to a seed extract of a new kenaf variety that can be domestically cultivated and harvested. It relates to an antibacterial composition against Gram-positive bacteria containing as an active ingredient. Kenaf ( Hibiscus cannabinus L.) seed extract of the long variety Kenaf (Kenaf, Hibiscus cannabinus L.), Korea Variety Protection Registration No. 4560, as an active ingredient in the broad-spectrum antibacterial composition of the present invention shows excellent antibacterial activity, and is used in antibacterial pharmaceutical compositions, health functional foods, and cosmetics. It has excellent effects that can be used for purposes such as compositions, animal feed compositions, food, cosmetics or additives for animal feed, various detergents, and various cleaning agents. In addition, the kenaf ( Hibiscus cannabinus L.) seed extract of the Korean variety protection registration number 4560 of the present invention has excellent heat stability and does not show loss of activity even under acidic conditions of pH 2 and in blood plasma. , it can be easily processed into various forms such as liquid, cream, powder, pills, and tablets, so it can be very useful in the pharmaceutical industry, food industry, livestock industry, health industry, and cosmetics industry.
Description
본 발명은 케나프(Kenaf, Hibiscus cannabinus L.) 종자 추출물을 유효성분으로 포함하는 항균 조성물에 관한 것으로서, 보다 구체적으로는, 보다 구체적으로는, 국내 재배 및 채종이 가능한 케나프 신품종 장대의 종자 추출물을 유효성분으로 포함하는 그람 양성 세균에 대한 항균 조성물에 관한 것이다.The present invention relates to an antibacterial composition containing kenaf ( Hibiscus cannabinus L.) seed extract as an active ingredient, and more specifically, to a seed extract of a new kenaf variety that can be domestically cultivated and harvested. It relates to an antibacterial composition against Gram-positive bacteria containing as an active ingredient.
인류는 병원성 미생물의 침입을 방어하고, 식품 부패 미생물을 제어하기 위하여 다양한 항균제와 방부제를 사용하여 왔다. 그러나, 화학 항균제 및 방부제의 경우, 다양한 세균과 진균에 우수한 항균력을 보이는 반면, 장기간 사용시에는 알러지(allergy)에 의한 발적, 혈관성 부종, 골수 억제, 빈혈, 위염, 퇴행성 뇌질환 등의 많은 부작용이 나타나게 된다. 실제 미국에서는 클로람페니콜(chloramphenicol) 등의 부작용이 심한 항생제 사용을 금지한 바 있다. 따라서, 안전성이 확보되어 있으면서 장기간 사용 경험이 있는 천연물을 이용한 천연 항균제 개발에 관한 다양한 연구가 진행 중에 있다.Humanity has used various antibacterial agents and preservatives to defend against invasion by pathogenic microorganisms and control food spoilage microorganisms. However, while chemical antibacterial agents and preservatives show excellent antibacterial activity against various bacteria and fungi, long-term use causes many side effects such as redness due to allergies, vascular edema, bone marrow suppression, anemia, gastritis, and degenerative brain disease. do. In fact, the United States has banned the use of antibiotics with severe side effects, such as chloramphenicol. Therefore, various studies are in progress on the development of natural antibacterial agents using natural products that are safe and have long-term use experience.
미국 질병관리예방센터(U.S. Center for Disease Control and Prevention)에 따르면, 병원 내 혈류 감염이 미국에서 주된 사망 원인 중 하나이다. 또한, 피부 및 연조직을 통한 병원성 세균 및 진균의 감염은 보편적인 의학적 질병으로 인식되어 있으며, 주로 외상 또는 수술에 의하여 유발되는 것으로 이해되고 있다. 많은 병원성 세균 및 진균의 감염은 감염의 중증도에 따라 그 처치 방법이 다르지만, 경구용 항미생물제 및 국소 청결로 성공적인 치료가 가능하다. 그러나, 근원적인 위험 인자(예를 들면, 혈관 혈류 이상, 당뇨) 및/또는 치료하기 어렵거나 다중-내성인 세균 및 진균에 의해 유발된 감염을 갖는 환자에서 흔히 발생하는 보다 심하거나 복잡한 감염은 정맥 내 항미생물제 치료 및 침입성 외과적 조직 제거 등의 조치가 필요할 수도 있다. 실례로, 글라이코펩타이드계 항생물질인 반코마이신은 다중-약물-내성 그람-양성균, 특히 MRSA, 응고효소-음성 스태필로코커스 및 엔테로코커스에 의해 야기된 심한 병원 내 감염에 대해 성공적으로 사용되어왔다. 그러나, 최근 반코마이신에 대해 내성을 갖는 균주의 분리가 증가하고 있음이 보고되고 있으며, 현재의 항생제로는 병원균 중 일부균에 의해 유발된 심한 감염에 대한 치료가 매우 제한되어 있는 것이 사실이다. 따라서, 점차 증가되고 있는 내성균에 대한 보다 효과적인 새로운 항생물질 개발의 필요성이 증가되고 있다.According to the U.S. Center for Disease Control and Prevention, hospital-acquired bloodstream infections are one of the leading causes of death in the United States. In addition, infection with pathogenic bacteria and fungi through skin and soft tissues is recognized as a common medical disease and is understood to be mainly caused by trauma or surgery. Many pathogenic bacterial and fungal infections can be treated successfully with oral antimicrobial agents and local cleansing, although treatment methods vary depending on the severity of the infection. However, more severe or complex infections commonly occur in patients with underlying risk factors (e.g., vascular blood flow abnormalities, diabetes) and/or infections caused by difficult-to-treat or multi-resistant bacteria and fungi. Treatment with antimicrobial agents and surgical removal of invasive tissue may be necessary. For example, vancomycin, a glycopeptide antibiotic, has been used successfully against severe nosocomial infections caused by multi-drug-resistant Gram-positive bacteria, especially MRSA, coagulase-negative Staphylococcus and Enterococcus. However, it has been reported that the isolation of strains resistant to vancomycin is increasing recently, and it is true that treatment of severe infections caused by some of the pathogens with current antibiotics is very limited. Therefore, the need to develop new, more effective antibiotics against the growing number of resistant bacteria is increasing.
한편, 케나프(Kenaf, Hibiscus cannabinus L.)는 서부 아프리카가 원산지인 무궁화과(Malvaceae)의 1년생 초본 식물로서, 척박한 건조 토양이나 습한 습지에서도 잘 자라며, 우수한 내염성, 내건성, 중금속 내성을 나타내어 아시아와 아프리카의 열대 및 아열대 지역에 광범위하게 재배되면서 토양 정화용 식물로 잘 알려져 있다. 또한, 빠른 생육과 함께 섬유로 이용 가능한 줄기의 특성으로 인해, 케나프는 아마, 대마, 황마와 함께 세계 4대 섬유작물로 알려져 있다. 섬유를 생산한 이후 케나프의 다양한 부위는 부산물로 생산되며, 잎과 줄기 분쇄물은 가축 사료로, 잎과 종자 오일은 해열, 진통, 항균 및 최음용의 식품 및 민간 처방으로 사용되어 왔다. Meanwhile, Kenaf ( Hibiscus cannabinus L.) is an annual herbaceous plant of the Malvaceae family native to West Africa. It grows well even in poor dry soil or wet wetlands, and exhibits excellent salt tolerance, drought tolerance, and heavy metal tolerance, making it a popular plant in Asia. It is widely cultivated in tropical and subtropical regions of Africa and is well known as a plant for soil purification. In addition, due to its rapid growth and the characteristics of its stems that can be used as fiber, kenaf is known as one of the world's four major fiber crops, along with flax, hemp, and jute. After producing fiber, various parts of kenaf are produced as by-products, the leaves and stem shreds are used as livestock feed, and the leaf and seed oil are used as food and folk remedies for antipyretic, analgesic, antibacterial and aphrodisiac properties.
국내에서는 2,000년대부터 케나프를 이용한 다양한 친환경 산업소재, 사료 및 기능성 식의약품 개발 연구가 진행되어 왔으며, 특히 국내 기후에 적합하면서 채종이 가능한 품종개량을 지속적으로 진행하여 왔으며, 마침내 2011년에 '장대' 품종을 개발하였다. 장대 품종은 외국산 케나프 품종을 한국원자력연구원에서 방사선 돌연변이 기술을 사용하여 육종한 신품종으로 수확량이 많고 국내 채종이 가능하여 2011년 국립종자원에 품종보호권을 출원(출원2011-26)하여 2013년 품종보호권이 등록(제4560호, 존속기간 2013. 6. 18 ~ 2033. 6. 17)되어 있다. In Korea, research has been conducted on the development of various eco-friendly industrial materials, feed, and functional food and pharmaceutical products using kenaf since the 2000s. In particular, we have continued to improve varieties that are suitable for the domestic climate and can be harvested, and finally in 2011, 'Jangdae' was launched. ' A variety was developed. The Jangdae variety is a new variety bred from a foreign kenaf variety using radiation mutation technology at the Korea Atomic Energy Research Institute. It has high yield and can be cultivated domestically, so it applied for variety protection rights to the National Seed Resources in 2011 (application 2011-26) and developed the variety in 2013. The protection right is registered (No. 4560, duration 2013. 6. 18 ~ 2033. 6. 17).
상기 장대 신품종은 기존 품종과 달리, 자엽 안토시아닌 색소 발현정도는 없거나 매우 약하고, 배축 안토시아닌 색소 발현정도는 없거나 매우 약하며, 줄기 안토시아닌 색소 발현 정도도 약한 특징을 가진다. 또한, 줄기 분지발생은 적고, 잎모양은 장상형이고, 결각의 깊이는 강하며, 잎 녹색정도는 중간이고, 꽃색은 노란색을 띈 흰색, 꽃 크기는 중간보다 크다. 삭과 크기는 중간, 삭과 안토시아닌 색소 발현 정도는 없거나 매우 약하고, 삭과 형태는 심장형이며, 국내에서 개화기는 9월 7일경, 성숙기는 10월 30일 경으로 알려져 있다. 특히, 종자의 경우 회색의 불규칙적인 모양을 나타내어, 기존 품종인 홍마의 붉은색의 불규칙적인 형태와 육안으로 쉽게 차별화된다. Unlike existing cultivars, the new longish variety has the characteristics of no or very weak expression of anthocyanin pigment in cotyledons, no or very weak expression of anthocyanin pigment in abaxial leaves, and weak expression of anthocyanin pigment in stem. In addition, there is little stem branching, the leaf shape is oblong, the depth of the notches is strong, the leaf greenness is medium, the flower color is yellowish white, and the flower size is larger than medium. The capsule size is medium, the expression of anthocyanin pigment in the capsule is absent or very weak, and the capsule shape is heart-shaped. In Korea, the flowering period is known to be around September 7 and the maturity period is around October 30. In particular, the seeds have a gray, irregular shape and are easily differentiated with the naked eye from the red, irregular shape of the existing variety, Hongma.
케나프와 관련된 연구는 주로 줄기껍질을 이용한 섬유 제조에 집중되어 있으며, 일부 종자와 잎에 대한 연구가 알려져 있다. 국내 채종이 가능한 케나프(Hibiscus cannabinus L.) 신품종 '장대'(강시용 외, 2016. 한국 Korean J. Breed. Sci. 48: 349-354), 케나프 신육성 및 수집 품종의 생육과 사료적 특성 조사(이지연 외, 2012. 한국작물학회지 57: 132-136), 친환경 소재 잣나무 목재와 케나프 줄기 혼합물의 항산화 및 미백효과(이용수 외, 2021. 한국생명과학회지 31: 305-313), 캐나프 잎의 항산화 활성을 보고한 추출조건에 따른 케나프(Hibiscus cannabinus L.)의 기능성 소재 탐색(손지민, 2019, 강원대학교 대학원 석사논문) 등이 알려져 있으며, 케나프 종자 추출물 및 오일의 암세포 사멸 효과(Wong TH et al., 2014. Asian Pac J Trop Biomed. 4(Suppl 1): S510-S515; Abd Ghafar SA et al., 2013. Evid Based Complement Alternat Med. 2013: 549705. doi: 10.1155/2013/549705), 케나프 종자의 고지혈증 억제효과(Kai NS et al., 2015. Asian Pac J Trop Med. 8: 6-13), 탈지 케나프 종자를 이용한 고지혈증 예방효과(Chan KW, 2018. Oxid Med Cell Longev. ;2018:6742571. doi: 10.1155/2018/6742571), 케나프 종자의 항산화 활성(Yusri NM, 2012, Molecules 17: 12612-12621), 케나프 오일 나노 이멀젼의 위궤양 억제활성(Cheong AM, 2018. Food Sci Biotechnol. 27: 1175-1184), 케나프 오일의 커피 음료 이용(Chew SC, 2020. J Food Sci Technol. 57: 2507-2515) 등이 보고되어 있다. 최근에는 히비스커스 식물의 hydroxychloroquine이 COVID-19와 관련된 혈전증 완화에 도움이 된다는 총설(Belizna C. et al., 2018. Autoimmunity Reviews, 17: 1153-1168)이 있으나, 케나프, 특히 장대와 관련성은 알려진 바 없다. Research related to kenaf is mainly focused on manufacturing fiber using stem bark, and research on some seeds and leaves is known. Kenaf ( Hibiscus cannabinus L.) new cultivar ‘Jangdae’ that can be cultivated domestically (Kang Si-yong et al., 2016. Korean J. Breed. Sci. 48: 349-354), growth and feed characteristics of new kenaf and collected cultivars Investigation (Lee Ji-yeon et al., 2012. Journal of the Korean Crop Society 57: 132-136), Antioxidant and whitening effect of eco-friendly material pine wood and kenaf stem mixture (Lee Yong-soo et al., 2021. Korean Journal of Life Sciences 31: 305-313), Canaf It is known that the search for functional materials of kenaf (Hibiscus cannabinus L.) according to the extraction conditions that reported the antioxidant activity of the leaves (Jimin Son, 2019, master's thesis from Kangwon National University Graduate School), and the cancer cell killing effect of kenaf seed extract and oil ( Wong TH et al., 2014. Asian Pac J Trop Biomed. 4(Suppl 1): S510-S515; Abd Ghafar SA et al., 2013. Evid Based Complement Alternat Med. doi: 10.1155/2013/549705. ), Hyperlipidemia suppression effect of kenaf seeds (Kai NS et al., 2015. Asian Pac J Trop Med. 8: 6-13), Hyperlipidemia prevention effect using defatted kenaf seeds (Chan KW, 2018. Oxid Med Cell Longev . ;2018:6742571. doi: 10.1155/2018/6742571), antioxidant activity of kenaf seeds (Yusri NM, 2012, Molecules 17: 12612-12621), gastric ulcer inhibition activity of kenaf oil nanoemulsion (Cheong AM, 2018) Food Sci Biotechnol. 27: 1175-1184), the use of kenaf oil in coffee drinks (Chew SC, 2020. J Food Sci Technol. 57: 2507-2515), etc. Recently, there is a review (Belizna C. et al., 2018. Autoimmunity Reviews, 17: 1153-1168) that hydroxychloroquine from the hibiscus plant helps alleviate thrombosis related to COVID-19, but its relationship with kenaf, especially thaliana, is unknown. There is no bar.
케나프와 관련된 특허로는 대한민국 등록특허 제10-2188643호에 [케나프(kenaf)의 신품종 장대(jangdae)를 주원료로 한 초식가축용 사료첨가제인 생균제의 제조방법], 등록특허 제10-0815476호에 [케나프 추출물과 이로부터 분리된 신규 캠프페롤 화합물 및 이의 용도], 등록특허 제10-0835710호에 [케나프 추출물과 이로부터 분리된 신규 캠프페롤 화합물 및 이의 식품으로의 용도], 등록특허 제10-0789737호에 [케나프 차 및 그의 제조방법], 등록특허 제10-0840558호에 [항염증 및 면역조절 활성을 가지는 케나프 추출물], 등록특허 제10-1844849호에 [헴프씨드 오일과 케나프씨드 오일을 함유하는 복합 조성물 및 그 제조 방법], 등록특허 제10-1293920호에 [나노케나프를 함유하는 폴리프로필렌 복합재료 조성물] 등이 개시되어 있으며, 대한민국 등록특허 제10-2260228호에 [케나프 종자 추출물을 유효성분으로 함유하는 항균용 조성물], 공개특허 제10-2021-0014256호에 [가용성 플라보노이드 및 폴리페놀의 함량을 증진시키는 케나프 종자의 가공방법 및 이의 가공물], 공개특허 제10-2010-0128946호에 [케나프 면사를 이용한 친환경 식생매트], 공개특허 제10-2011-0092482호에 [원적외선 건조로 항균활성이 증가된 케나프 잎 추출물 및 이의 제조방법]이 공개되어 있다. 그러나, 현재까지 케나프 종자, 특히 국내에서 생산되는 신품종 장대 종자 추출물의 항균 활성에 대한 특허는 알려진 바 없다.Patents related to kenaf include Republic of Korea Patent No. 10-2188643 [Method for manufacturing probiotics, a feed additive for herbivorous livestock using jangdae, a new variety of kenaf, as the main ingredient], and Registration Patent No. 10-0815476. Registered in Patent No. 10-0835710 [Kenaf extract and new kaempferol compound isolated therefrom and its use in food], registered in Patent No. 10-0835710 [Kenaf extract and new kaempferol compound isolated therefrom and its use in food]. Patent No. 10-0789737 [Kenaf tea and its manufacturing method], Patent No. 10-0840558 [Kenaf extract with anti-inflammatory and immunomodulatory activity], and Patent No. 10-1844849 [Hemp Seed] Composite composition containing oil and kenaf seed oil and method for producing the same], [Polypropylene composite material composition containing nanokenaf], etc. are disclosed in Registered Patent No. 10-1293920, and Republic of Korea Patent No. 10- In No. 2260228 [An antibacterial composition containing kenaf seed extract as an active ingredient], in Patent Publication No. 10-2021-0014256 [Method for processing kenaf seeds and processed products thereof to increase the content of soluble flavonoids and polyphenols] , in Publication Patent No. 10-2010-0128946 [Eco-friendly vegetation mat using kenaf cotton yarn], in Publication Patent No. 10-2011-0092482 [Kenaf leaf extract with increased antibacterial activity by far-infrared drying and method for manufacturing the same] This is public. However, to date, there are no known patents on the antibacterial activity of kenaf seeds, especially the extract of the new domestically produced plant species.
본 발명은 상기와 같은 종래 기술의 문제점을 해결하기 위하여 안출된 것으로서, 본 발명에서 해결하고자 하는 과제는 케나프(Kenaf, Hibiscus cannabinus L.) 종자 추출물을 유효성분으로 함유하는 항균 조성물을 제공하고자 하는 것이다.The present invention was made to solve the problems of the prior art as described above, and the problem to be solved by the present invention is to provide an antibacterial composition containing kenaf ( Hibiscus cannabinus L.) seed extract as an active ingredient. will be.
상기와 같은 과제를 해결하기 위하여, 본 발명은 대한민국 품종보호권 등록번호 제4560호인 장대 품종의 케나프(Kenaf, Hibiscus cannabinus L.) 종자 추출물을 포함하는 항균 조성물을 제공한다.In order to solve the above problems, the present invention provides an antibacterial composition containing a seed extract of Kenaf ( Hibiscus cannabinus L.) of the long plant variety, which is Korea Variety Protection Registration No. 4560.
상기 추출물은 에탄올 추출물인 것이 바람직하다.The extract is preferably an ethanol extract.
상기 항균은 그람 양성 세균, 그람 음성 세균 또는 진균에 대한 것이 바람직하다.The antibacterial agent is preferably against gram-positive bacteria, gram-negative bacteria, or fungi.
상기 조성물은 약학 조성물, 건강 기능 식품, 화장료 조성물, 동물 사료 조성물, 식품 첨가물, 화장품 첨가물, 동물 사료용 첨가물, 세정제 및 청결제로 이루어지는 군으로부터 선택되는 것이 바람직하다.The composition is preferably selected from the group consisting of pharmaceutical compositions, health functional foods, cosmetic compositions, animal feed compositions, food additives, cosmetic additives, additives for animal feed, detergents, and cleaning agents.
본 발명의 광범위 항균 조성물의 유효성분으로서의 대한민국 품종보호권 등록번호 제4560호인 장대 품종의 케나프(Kenaf, Hibiscus cannabinus L.) 종자 추출물은 우수한 항균 활성을 나타내어, 항균용 약학 조성물, 건강 기능 식품, 화장료 조성물, 동물 사료 조성물, 식품, 화장품 또는 동물 사료용 첨가물, 각종 세정제 및 각종 청결제 등의 용도로 사용할 수 있는 뛰어난 효과가 있다. 뿐만 아니라, 본 발명의 대한민국 품종보호권 등록번호 제4560호인 장대 품종의 케나프(Kenaf, Hibiscus cannabinus L.) 종자 추출물은 열 안정성이 우수하고, pH 2의 산성조건 및 혈장 내에서도 활성의 손실이 나타나지 않아, 액상, 크림, 분말, 환, 정 등의 다양한 형태로 손쉽게 가공될 수 있어 제약 산업, 식품 산업, 축산업, 보건 산업 및 화장품 산업상 매우 유용하게 이용될 수 있다.Kenaf ( Hibiscus cannabinus L.) seed extract of the long variety Kenaf (Kenaf, Hibiscus cannabinus L.), Korea Variety Protection Registration No. 4560, as an active ingredient in the broad-spectrum antibacterial composition of the present invention shows excellent antibacterial activity, and is used in antibacterial pharmaceutical compositions, health functional foods, and cosmetics. It has excellent effects that can be used for purposes such as compositions, animal feed compositions, food, cosmetics or additives for animal feed, various detergents, and various cleaning agents. In addition, the kenaf ( Hibiscus cannabinus L.) seed extract of the Korean variety protection registration number 4560 of the present invention has excellent heat stability and does not show loss of activity even under acidic conditions of pH 2 and in blood plasma. , it can be easily processed into various forms such as liquid, cream, powder, pills, and tablets, so it can be very useful in the pharmaceutical industry, food industry, livestock industry, health industry, and cosmetics industry.
도 1은 케나프 종자의 품종별 사진을 나타낸 것이다.Figure 1 shows photos of kenaf seeds by variety.
이하, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 발명자들은 케나프(Kenaf, Hibiscus cannabinus L.) 종자 추출물의 항균 효능을 검증하기 위하여, 품종별로 케나프 종자 추출물을 각각 조제하고, 이들의 항세균 및 항진균 활성을 평가한 결과, 대한민국 품종보호권 등록번호 제4560호인 장대 품종의 케나프 종자 추출물에서 광범위 항균 활성을 확인하였으며, 상기 분획물은 인간 적혈구에 대해 용혈 활성은 전혀 나타내지 않으면서도, 열 안정성과 산 안정성이 우수한 특징을 가짐을 확인함으로서 상기 대한민국 품종보호권 등록번호 제4560호인 장대 품종의 케나프 종자 추출물을 그람 양성 세균, 그람 음성 세균 및 진균 감염병에 대한 광범위 항균제로 개발될 수 있음을 확인하여 본 발명을 완성하였다.In order to verify the antibacterial efficacy of kenaf ( Hibiscus cannabinus L.) seed extract, the inventors of the present invention prepared kenaf seed extracts for each variety and evaluated their antibacterial and antifungal activities. As a result, the Korean variety Broad-spectrum antibacterial activity was confirmed in the kenaf seed extract of the Pole cultivar, protection registration number 4560, and it was confirmed that the fraction showed no hemolytic activity against human red blood cells and had excellent heat stability and acid stability. The present invention was completed by confirming that the kenaf seed extract of the pole variety, which is Korean Variety Protection Registration No. 4560, can be developed as a broad-spectrum antibacterial agent against Gram-positive bacteria, Gram-negative bacteria, and fungal infectious diseases.
구체적으로, 본 발명자들은 케나프 종자 추출물에서 항균 물질을 개발하기 위하여, 품종별 케나프 종자의 특성 분석에 이어, 상기 시료들을 대상으로 에탄올 추출물을 각각 조제하고 이들의 항균 활성을 평가하였으며, 장대 품종의 케나프 종자 에탄올 추출물에서 강력한 항세균 및 항진균 활성을 확인하였다. 또한, 상기 추출물은 인간 적혈구에 대한 용혈 활성은 나타내지 않음을 확인하였다. Specifically, in order to develop antibacterial substances from kenaf seed extract, the present inventors analyzed the characteristics of kenaf seeds for each variety, prepared ethanol extracts for each of the samples, and evaluated their antibacterial activity. Strong antibacterial and antifungal activity was confirmed in the ethanol extract of kenaf seeds. Additionally, it was confirmed that the extract did not exhibit hemolytic activity against human red blood cells.
따라서, 본 발명은 대한민국 품종보호권 등록번호 제4560호인 장대 품종의 케나프(Kenaf, Hibiscus cannabinus L.) 종자 추출물을 포함하는 항균 조성물을 제공한다.Accordingly, the present invention provides an antibacterial composition containing a seed extract of Kenaf ( Hibiscus cannabinus L.) of the long plant variety, which is Korean Variety Protection Registration No. 4560.
상기 추출물은 에탄올 추출물인 것이 바람직하다.The extract is preferably an ethanol extract.
상기 항균은 그람 양성 세균, 그람 음성 세균 또는 진균에 대한 것이 바람직하다.The antibacterial agent is preferably against gram-positive bacteria, gram-negative bacteria, or fungi.
상기 조성물은 약학 조성물, 건강 기능 식품, 화장료 조성물, 동물 사료 조성물, 식품 첨가물, 화장품 첨가물, 동물 사료용 첨가물, 세정제 및 청결제로 이루어지는 군으로부터 선택되는 것이 바람직하다.The composition is preferably selected from the group consisting of pharmaceutical compositions, health functional foods, cosmetic compositions, animal feed compositions, food additives, cosmetic additives, additives for animal feed, detergents, and cleaning agents.
이하에서는, 본 발명의 장대 품종의 케나프 종자 추출물의 제조 방법 및 효능 실험 등을 보다 구체적으로 설명한다.Hereinafter, the production method and efficacy test of the kenaf seed extract of the pole variety of the present invention will be described in more detail.
본 발명은 품종별 케나프 종자를 준비하는 단계; 상기 시료로부터 추출물을 조제하는 단계; 상기 추출물의 항세균 및 항진균 활성 평가 단계; 활성 추출물의 안정성 및 인간 적혈구 용혈활성 조사 단계를 포함한다.The present invention includes the steps of preparing kenaf seeds for each variety; Preparing an extract from the sample; Evaluation of antibacterial and antifungal activity of the extract; It includes steps to investigate the stability and human red blood cell hemolytic activity of the active extract.
본 발명의 조성물에 포함되는 "장대 품종의 케나프 종자 추출물"은 성숙된 장대 품종의 케나프 종자를 회수하는 단계; 회수 종자에서 이물질을 제거하고 분쇄하는 단계; 상기 분쇄된 케나프 종자를 용매로 추출하는 단계 및 상기 추출액을 0.06mm 이하의 여과망을 사용하여 여과하고, 이를 감압농축하는 단계에 의해 수득될 수 있다.The “Kenaf seed extract of the long-haired variety” included in the composition of the present invention includes the steps of: recovering mature kenaf seeds of the long-haired variety; Removing foreign substances from recovered seeds and grinding them; It can be obtained by extracting the pulverized kenaf seeds with a solvent, filtering the extract using a filter mesh of 0.06 mm or less, and concentrating it under reduced pressure.
본 발명에서 사용되는 용매는 물(냉수, 열수), 주정, 탄소수 1~4의 무수 또는 함수 저급 알코올(메탄올, 에탄올, 주정, 프로판올, 부탄올 등), 상기 저급알코올과 물과의 혼합용매 등을 이용할 수 있으며, 에탄올 추출이 가장 바람직하다.Solvents used in the present invention include water (cold water, hot water), alcohol, anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms (methanol, ethanol, alcohol, propanol, butanol, etc.), mixed solvents of the lower alcohols and water, etc. It can be used, and ethanol extraction is most preferred.
상기 추출물, 바람직하게는 에탄올 추출물은 헥센, 에틸아세테이트 및 부탄올의 유기용매로 순차 또는 각각 분획하여 헥센 분획물, 에틸아세테이트 분획물, 부탄올 분획물 및 유기용매 분획 후의 물 잔류물을 추가적으로 수득할 수 있다.The extract, preferably the ethanol extract, can be sequentially or separately fractionated with organic solvents of hexene, ethyl acetate, and butanol to additionally obtain a hexene fraction, ethyl acetate fraction, butanol fraction, and water residue after organic solvent fractionation.
본 발명의 장대 품종의 케나프 종자 추출물은 감압건조 및 동결건조, 또는 분무건조 등과 같은 통상적인 분말화 과정을 거쳐 분말로 제조될 수 있다. 이들은 혈장 내의 다양한 분해효소에 분해되지 않으며, 100 ℃의 열처리와 pH 2의 인체 위 내의 pH에서도 활성을 유지한다.The kenaf seed extract of the pole variety of the present invention can be manufactured into powder through a conventional powdering process such as reduced pressure drying, freeze drying, or spray drying. They are not decomposed by various decomposition enzymes in plasma, and remain active even at heat treatment at 100°C and pH 2 in the human stomach.
본 발명의 장대 품종의 케나프 종자 추출물은 강력한 항균 활성을 나타내어, 병원성 세균의 감염의 예방 또는 치료와 관련되는 약학 조성물, 건강 기능 식품, 화장료 조성물, 동물 사료 조성물, 식품, 화장품, 동물 사료용 첨가물 및 각종 청결제의 소재로 사용될 수 있다.The kenaf seed extract of the plant species of the present invention exhibits strong antibacterial activity, and is used in pharmaceutical compositions, health functional foods, cosmetic compositions, animal feed compositions, foods, cosmetics, additives for animal feed, etc. related to the prevention or treatment of infection by pathogenic bacteria. It can be used as a material for various cleaning agents.
바람직한 구체예로서, 본 발명의 항균 조성물은 약학적 조성물의 용도로서 적용될 수 있다. As a preferred embodiment, the antibacterial composition of the present invention can be applied as a pharmaceutical composition.
상기 약학적 조성물은 각각의 사용 목적에 맞게 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁제, 에멀젼, 시럽, 에어로졸 등의 경구 제형, 멸균 주사용액의 주사제 등 다양한 형태로 제형화하여 사용할 수 있으며, 경구 투여하거나 정맥 내, 복강 내, 피하, 직장, 국소 투여 등을 포함한 다양한 경로를 통해 투여될 수 있다. 이러한 약학적 조성물에는 추가적으로 담체, 부형제 또는 희석제 등이 더 포함될 수 있으며, 포함될 수 있는 적합한 담체, 부형제 또는 희석제의 예로는 락토오스, 덱스트로오스, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에리쓰리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로스, 메틸 셀룰로스, 비정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 들 수 있다. 또한, 본 발명의 약학적 조성물은 충전제, 항응집제, 윤활제, 습윤제, 향료, 유화제, 방부제 등을 추가로 더 포함할 수도 있다. The pharmaceutical composition is formulated into various forms such as oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., and injections of sterile injectable solutions according to conventional methods to suit each purpose of use. It can be used orally or administered through a variety of routes, including intravenous, intraperitoneal, subcutaneous, rectal, and topical administration. These pharmaceutical compositions may additionally contain carriers, excipients or diluents, and examples of suitable carriers, excipients or diluents that may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, Starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, amorphous cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. etc. can be mentioned. In addition, the pharmaceutical composition of the present invention may further include fillers, anti-coagulants, lubricants, wetting agents, flavorings, emulsifiers, preservatives, etc.
본 발명의 약학적 조성물은 약제학적으로 유효한 양으로 투여한다. 본 발명에서, "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고, 종래의 치료제와 순차적으로 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기한 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다. The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, “pharmaceutically effective amount” means an amount sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type, severity, activity of the drug, and the type and severity of the patient's disease. It can be determined based on factors including sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the field of medicine. The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. Considering all of the above factors, it is important to administer an amount that can achieve maximum effect with the minimum amount without side effects, and this can be easily determined by a person skilled in the art.
본 발명의 약학적 조성물에서 항균 활성을 갖는 성분의 유효량은 환자의 나이, 성별, 체중에 따라 달라질 수 있으며, 일반적으로는 체중 당 1 내지 5,000mg, 바람직하게는 100 내지 3,000mg을 매일 또는 격일 투여하거나 1일 1 내지 3회로 나누어 투여할 수 있다. 그러나, 투여 경로, 질병의 중증도, 성별, 체중, 연령 등에 따라서 증감될 수 있으므로 상기 투여량이 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다. 본 발명의 약학적 조성물은 다양한 경로를 통하여 대상에 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관 내(intra-cerebroventricular) 주사에 의해 투여될 수 있다. 본 발명에서 "투여"는 임의의 적절한 방법으로 환자에게 소정의 물질을 제공하는 것을 의미하며, 본 발명의 약학적 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 일반적인 모든 경로를 통하여 경구 또는 비경구 투여될 수 있다. 또한, 본 발명의 조성물은 유효성분을 표적 세포로 전달할 수 있는 임의의 장치를 이용해 투여될 수도 있다. 본 발명에서 "대상"은, 특별히 한정되는 것은 아니지만, 예를 들어, 인간, 원숭이, 소, 말, 양, 돼지, 닭, 칠면조, 메추라기, 고양이, 개, 마우스, 쥐, 토끼 또는 기니아 피그를 포함하고, 바람직하게는 포유류, 보다 바람직하게는 인간을 의미한다. The effective amount of the ingredient with antibacterial activity in the pharmaceutical composition of the present invention may vary depending on the patient's age, gender, and weight, and is generally administered at 1 to 5,000 mg per body weight, preferably 100 to 3,000 mg every day or every other day. Alternatively, it can be administered in divided doses 1 to 3 times a day. However, since it may increase or decrease depending on the route of administration, severity of disease, gender, weight, age, etc., the above dosage does not limit the scope of the present invention in any way. The pharmaceutical composition of the present invention can be administered to a subject through various routes. All modes of administration are contemplated, for example, oral, rectal or by intravenous, intramuscular, subcutaneous, intrauterine intrathecal or intra-cerebroventricular injection. In the present invention, “administration” means providing a predetermined substance to a patient by any appropriate method, and the route of administration of the pharmaceutical composition of the present invention is oral or parenteral through all general routes as long as it can reach the target tissue. It can be administered orally. Additionally, the composition of the present invention may be administered using any device capable of delivering the active ingredient to target cells. In the present invention, “subject” includes, but is not particularly limited to, for example, humans, monkeys, cows, horses, sheep, pigs, chickens, turkeys, quail, cats, dogs, mice, rats, rabbits or guinea pigs. And, preferably, it means a mammal, and more preferably, a human.
바람직한 구체예로서, 본 발명의 항균 조성물은 건강 기능 식품의 용도로서 적용될 수 있다. As a preferred embodiment, the antibacterial composition of the present invention can be applied as a health functional food.
본 발명의 건강 기능 식품은 병원성 미생물의 감염 우려가 높은 대상으로부터 감염의 가능성을 낮추어 줄 수 있는 효과적인 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 항균 활성이 우수한 유효성분을 포함하는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다. 본 발명의 활성 성분은 일반적으로 전체 식품 중량의 0.01 내지 15중량%로 가할 수 있으며, 건강음료 조성물은 100 ml를 기준으로 0.02 내지 10g, 바람직하게는 0.3 내지 1g의 비율로 가할 수 있다. 본 발명의 건강 기능 식품은 지시된 비율로 필수 성분으로서 상기 화합물을 함유하는 것 외에 식품학적으로 허용 가능한 식품보조 첨가제, 예컨대, 천연 탄수화물 및 다양한 향미제 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물의 예로는 포도당, 과당 등의 단당류, 말토오스, 수크로오스 등의 이당류 및 덱스트린, 시클로덱스트린 등의 다당류와 같은 통상적인 당 및 자일리톨, 소르비톨, 에리쓰리톨 등의 당알코올이 있다. 상기 향미제로는 타우마틴, 레바우디오시드 A, 글리시르히진, 사카린, 아스파르탐 등을 사용할 수 있다. 상기 향미제의 비율은 본 발명의 건강 기능 식품 100ml당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g을 사용한다. 상기 외에 본 발명의 건강 기능 식품은 여러 가지 영양제, 비타민, 광물, 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강 기능 식품은 천연 과일 주스 및 과일 주스 음료 및 야채 음료 등의 제조를 위한 과육을 함유할 수도 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 본 발명의 상기 활성 분획물 100 중량부 당 0.01 내지 약 20중량부의 범위에서 선택되는 것이 일반적이다. The health functional food of the present invention can be used in a variety of ways, such as effective foods and beverages that can reduce the possibility of infection from subjects at high risk of infection with pathogenic microorganisms. Foods containing the active ingredient with excellent antibacterial activity of the present invention include, for example, various foods, beverages, gums, teas, vitamin complexes, health supplements, etc., and may be taken in the form of powders, granules, tablets, capsules, or beverages. It can be used as The active ingredient of the present invention can generally be added at 0.01 to 15% by weight of the total food weight, and the health drink composition can be added at a rate of 0.02 to 10g, preferably 0.3 to 1g, based on 100 ml. In addition to containing the above compounds as essential ingredients in the indicated ratio, the health functional food of the present invention may contain foodologically acceptable food additives, such as natural carbohydrates and various flavoring agents, as additional ingredients. Examples of the natural carbohydrates include common sugars such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. The flavoring agent may include thaumatin, rebaudioside A, glycyrrhizin, saccharin, and aspartame. The ratio of the flavoring agent is generally about 1 to 20 g, preferably about 5 to 12 g, per 100 ml of the health functional food of the present invention. In addition to the above, the health functional food of the present invention contains various nutrients, vitamins, minerals, flavoring agents such as synthetic and natural flavors, colorants and thickening agents, pectic acid and its salts, alginic acid and its salts, organic acids, and protective colloids. It may contain thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the health functional food of the present invention may contain pulp for the production of natural fruit juice, fruit juice drinks, vegetable drinks, etc. These ingredients can be used independently or in combination. The ratio of these additives is generally selected in the range of 0.01 to about 20 parts by weight per 100 parts by weight of the active fraction of the present invention.
바람직한 구체예로서, 본 발명의 항균 조성물은 화장료 조성물의 용도로서 적용될 수 있다. As a preferred embodiment, the antibacterial composition of the present invention can be applied as a cosmetic composition.
본 발명의 화장료 조성물은 본 발명의 항균 활성이 우수한 성분을, 예를 들어, 에센스, 영양크림, 바디로션, 린스, 샴푸, 바디클렌저, 로션, 스킨, 마스크팩 등의 형태로 제조될 수 있으며, 여기에 한정되는 것은 아니다. 상기 형태로의 제조는 당업자에게 알려진 다양한 제조 공정에 따라 용이하게 수행될 수 있을 것이다.The cosmetic composition of the present invention can be manufactured using the ingredients having excellent antibacterial activity of the present invention in the form of, for example, essence, nutritional cream, body lotion, rinse, shampoo, body cleanser, lotion, skin, mask pack, etc. It is not limited to this. Manufacturing in the above form can be easily performed according to various manufacturing processes known to those skilled in the art.
바람직한 구체예로서, 본 발명의 항균 조성물은 동물 사료 조성물의 용도로서 적용될 수 있다. As a preferred embodiment, the antibacterial composition of the present invention can be applied as an animal feed composition.
상기 동물은 식물에 대응하는 생물군으로 주로 유기물을 영양분으로 섭취하며, 소화나 배성 및 호흡기관이 분화되어 있는 것을 말하고, 구체적으로는 극피동물, 갑각류, 연체동물, 어류, 양서류, 파충류, 조류, 포유류일 수 있으며, 바람직하게는 성게류 또는 해삼류와 같은 극피동물, 게, 새우, 대하 등의 갑각류를 포함하는 절지동물, 두족류, 복족류 또는 이매패류 등의 연체동물, 참돔, 도미, 대구, 가자미, 넙치 등의 어류, 꿩 또는 닭 등의 가금류를 포함하는 조류 또는 돼지, 소, 염소 등의 포유류일 수 있다.The above-mentioned animals are a group of organisms corresponding to plants and mainly consume organic matter as nutrients and have differentiated digestive, excretory and respiratory organs. Specifically, they include echinoderms, crustaceans, molluscs, fish, amphibians, reptiles, birds, It may be a mammal, preferably echinoderms such as sea urchins or sea cucumbers, arthropods including crustaceans such as crabs, shrimp, and prawns, molluscs such as cephalopods, gastropods, or bivalves, red sea bream, sea bream, cod, and flounder. , it may be fish such as flounder, birds including poultry such as pheasant or chicken, or mammals such as pigs, cows, and goats.
상기 동물 사료용 조성물은 본 발명의 항균 성분을 포함하는 항균 조성물에 곡물, 식물성 단백질 사료, 동물성 단백질 사료, 당분 또는 유제품을 추가로 포함할 수 있다. 상기 곡물은 구체적으로는 분쇄 또는 파쇄된 밀, 귀리, 보리, 옥수수 및 쌀일 수 있고, 상기 식물성 단백질 사료는 구체적으로는 평지, 콩 및 해바라기를 주성분으로 하는 것일 수 있으며, 상기 동물성 단백질 사료는 구체적으로는 혈분, 육분, 골분 및 생선분일 수 있고, 상기 당분 또는 유제품은 구체적으로는 각종 분유 및 유장 분말로 이루어지는 건조성분일 수 있다.The composition for animal feed may further include grains, vegetable protein feed, animal protein feed, sugar, or dairy products in an antibacterial composition containing the antibacterial ingredient of the present invention. The grain may specifically be ground or crushed wheat, oats, barley, corn and rice, the vegetable protein feed may specifically be composed of rape, soybean and sunflower as main ingredients, and the animal protein feed may specifically be May be blood meal, meat meal, bone meal, and fish meal, and the sugar or dairy product may specifically be a dry ingredient made of various powdered milk and whey powder.
상기 동물 사료용 조성물은 추가로 영양 보충제, 소화 및 흡수 향상제, 성창 촉진제 또는 질병 예방제와 같은 성분을 함께 사용할 수 있다.The composition for animal feed may additionally contain ingredients such as nutritional supplements, digestion and absorption enhancers, voice prolonging agents, or disease prevention agents.
본 발명의 동물 사료용 조성물에 포함되는 항균 조성물은 사료의 사용목적 및 사용조건에 따라 달라질 수 있으며, 일 예로 최종 생산된 사료 1kg을 기준으로 상기 항균성 조성물이 0.1g 내지 100g 포함될 수 있다.The antibacterial composition included in the composition for animal feed of the present invention may vary depending on the purpose and conditions of use of the feed. For example, 0.1 g to 100 g of the antibacterial composition may be included based on 1 kg of final produced feed.
또한, 상기 사료 조성물은 성분들의 분쇄 정도에 따라 경점성의 조립 또는 과립 물질로 제조될 수 있으며, 상기 조성물은 메쉬로 공급되거나 추가 가공 및 포장을 위해 원하는 분리된 형상으로 형성시킬 수 있으며, 저장을 위해 펠렛화, 팽창화 또는 압출 공정을 거칠 수 있으며, 저장의 용이성을 위해 바람직하게는 과잉의 물을 건조 제거될 수 있다.Additionally, the feed composition can be manufactured into a lightly viscous granular or granular material depending on the degree of grinding of the ingredients, and the composition can be supplied as a mesh or formed into a desired discrete shape for further processing and packaging, and storage. For this purpose, it may be subjected to a pelletizing, expanding or extruding process, and for ease of storage, excess water may preferably be removed by drying.
바람직한 구체예로서, 본 발명의 항균 조성물은 식품, 화장품 또는 동물 사료용 첨가제의 용도로서 적용될 수 있다. As a preferred embodiment, the antibacterial composition of the present invention can be applied as an additive for food, cosmetics, or animal feed.
상기 첨가제는 사용되는 식품, 화장품 또는 동물 사료에 보존성을 부여하기 위하여 첨가되는 것으로서, 상기 항균 조성물은 천연성분으로 인체에 유해하지 아니하므로 식품, 화장품 또는 동물용 사료에 안전하게 적용할 수 있다.The additive is added to provide preservability to food, cosmetics, or animal feed. Since the antibacterial composition is a natural ingredient and is not harmful to the human body, it can be safely applied to food, cosmetics, or animal feed.
상기 첨가제는 그 사용 목적 및 용도에 따라 적의 선택된 추가적인 여타의 첨가물을 추가로 더 포함할 수 있으며, 통상적으로 사용되는 첨가물 등 다른 유효성분이나 색소, 계면활성제, 방부제 등의 첨가물과 혼합하여 사용할 수 있다. 상기 첨가제는 그 사용 목적 및 용도에 따라 분말화, 과립화, 정제화 또는 액상화하여 제조될 수 있으며, 제품화를 위하여 포장을 위해 통상의 방법을 사용할 수 있다.The additive may further include other additives appropriately selected depending on the purpose and purpose of use, and may be used by mixing with other active ingredients such as commonly used additives or additives such as pigments, surfactants, and preservatives. . The additives can be manufactured by powdering, granulating, tableting or liquefying depending on the purpose and purpose of use, and conventional methods can be used for packaging for commercialization.
또한, 상기 첨가제 중 항균 조성물의 사용량은 사용목적과 적용형태, 적용부위, 적용대상물품 등에 따라 적절히 사용될 수 있으며, 예를 들면 전체 조성물 기준으로 0.01 중량부 내지 50 중량부를 포함할 수 있으나, 상기 항균 조성물의 함량은 이에 한정되는 것은 아니다. 본원 발명의 항균 조성물은 천연성분으로 인체에 유해하지 아니하므로, 그 제품의 특성상 적용목적을 달성할 수 있는 경우라면 다양한 양으로 사용가능하다.In addition, the amount of the antibacterial composition among the above additives may be appropriately used depending on the purpose of use, application type, application area, application target, etc., for example, may include 0.01 parts by weight to 50 parts by weight based on the total composition, but the antibacterial composition The content of the composition is not limited to this. Since the antibacterial composition of the present invention is a natural ingredient and is not harmful to the human body, it can be used in various amounts as long as it can achieve the purpose of application due to the nature of the product.
바람직한 구체예로서, 본 발명은 항균 조성물은 세정제의 용도로서 적용될 수 있다.As a preferred embodiment, the antibacterial composition of the present invention can be applied as a detergent.
상기 세정제는 바람직하게는 의류용 세제, 식기 세척제, 식품 세정제, 가전제품 세척제일 수 있다. 상기 항균 조성물은 천연성분으로 인체에 유해하지 아니하므로, 더욱 바람직하게는 주방용품 또는 식품세척 등을 포함하는 각종 생활용품의 세척이나 항균성 부여를 목적으로 사용할 수 있다.The detergent may preferably be a clothing detergent, dishwashing detergent, food detergent, or home appliance detergent. Since the antibacterial composition is a natural ingredient and is not harmful to the human body, it can be more preferably used for cleaning various household products, including kitchen utensils or food cleaners, or for imparting antibacterial properties.
상기 세정제는 그 사용 목적 및 용도에 따라 적의 선택된 첨가물을 추가로 포함할 수 있으며, 통상적으로 사용되는 세정제 등 다른 유효성분이나 색소, 계면활성제, 방부제 등의 첨가제와 혼합하여 사용할 수 있다. 상기 세정제는 그 사용 목적 및 용도에 따라 분말화, 과립화, 정제화 또는 액상화하여 제조될 수 있으며, 제품화를 위하여 포장을 위해 통상의 방법을 사용할 수 있다.The detergent may further contain selected additives depending on its purpose and use, and may be mixed with other active ingredients such as commonly used detergents or additives such as pigments, surfactants, and preservatives. The detergent can be manufactured by powdering, granulating, tableting or liquefying depending on its purpose and purpose, and conventional methods can be used for packaging for commercialization.
또한, 상기 세정제 중 항균성 조성물의 사용량은 사용목적과 적용형태, 적용부위, 적용대상물품 등에 따라 적절히 사용될 수 있으며, 예를 들면 전체 조성물 기준으로 0.01 중량부 내지 50 중량부를 포함할 수 있으나, 상기 항균성 조성물의 함량은 이에 한정되는 것은 아니다. 본원 발명의 항균성 조성물은 천연성분으로 인체에 유해하지 아니하므로, 그 제품의 특성상 적용목적을 달성할 수 있는 경우라면 다양한 양으로 사용가능하다.In addition, the amount of the antibacterial composition used in the detergent may be appropriately used depending on the purpose of use, application type, application area, application target, etc., for example, it may include 0.01 parts by weight to 50 parts by weight based on the total composition, but the antibacterial effect The content of the composition is not limited to this. Since the antibacterial composition of the present invention is a natural ingredient and is not harmful to the human body, it can be used in various amounts as long as it can achieve the application purpose due to the nature of the product.
바람직한 구체예로서, 본 발명은 항균 조성물은 청결제의 용도로서 적용될 수 있다.As a preferred embodiment, the antibacterial composition of the present invention can be applied as a cleaning agent.
상기 청결제는 일상 생활에서 흔히 감염되기 쉬운 병원성 미생물의 체내 감염을 예방 차원에서 수행하기 위하여 간단한 방법으로 손, 구강 또는 여성용 청결제 등의 용도로 사용될 수 있다. 상기 항균 조성물은 천연성분으로 인체에 유해하지 아니하므로 손, 구강, 여성용 청결제로 사용하는 경우에도 안전하게 적용할 수 있다.The cleaning agent can be used as a hand, mouth, or feminine cleanser in a simple way to prevent infection of the body by pathogenic microorganisms that are commonly susceptible to infection in daily life. The antibacterial composition is a natural ingredient and is not harmful to the human body, so it can be safely applied even when used as a cleanser for hands, mouth, and women.
상기 청결제는 그 사용 목적 및 용도에 따라 적의 선택된 추가적인 여타의 첨가물을 추가로 더 포함할 수 있으며, 통상적으로 사용되는 첨가물 등 다른 유효성분이나 색소, 계면활성제, 방부제 등의 첨가물과 혼합하여 사용할 수 있다. 상기 청결제는 그 사용 목적 및 용도에 따라 분말화, 과립화, 정제화 또는 액상화하여 제조될 수 있으나, 액상형의 경우 편리한 사용이 가능할 것이다.The cleaning agent may further contain other additives appropriately selected depending on its purpose and use, and may be used by mixing with other active ingredients such as commonly used additives or additives such as pigments, surfactants, and preservatives. . The cleaning agent can be manufactured by powdering, granulating, tableting, or liquidizing depending on the purpose and purpose of use. However, convenient use will be possible in the liquid form.
또한, 상기 청결제 중 항균 조성물의 사용량은 사용목적과 적용형태, 적용부위 등에 따라 적절히 사용될 수 있으며, 예를 들면 전체 조성물 기준으로 0.01중량부 내지 50중량부를 포함할 수 있으나, 상기 항균 조성물의 함량은 이에 한정되는 것은 아니다. 본원 발명의 항균 조성물은 천연성분으로 인체에 유해하지 아니하므로, 그 제품의 특성상 적용목적을 달성할 수 있는 경우라면 다양한 양으로 사용가능하다.In addition, the amount of the antibacterial composition used in the cleaning agent may be appropriately used depending on the purpose of use, application type, application area, etc., for example, it may include 0.01 parts by weight to 50 parts by weight based on the total composition, but the content of the antibacterial composition is It is not limited to this. Since the antibacterial composition of the present invention is a natural ingredient and is not harmful to the human body, it can be used in various amounts as long as it can achieve the purpose of application due to the nature of the product.
이하에서는 실시예를 통하여 본 발명을 더욱 상세하게 설명한다. 하기 실시예는 본 발명의 바람직한 일 구체예일 뿐이며, 본 발명의 권리범위가 하기 실시예의 범위로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. The following example is only a preferred embodiment of the present invention, and the scope of the present invention is not limited to the scope of the following example.
[실시예][Example]
실시예 1: 다양한 케나프 종자 확보 및 종자들의 특성 평가 Example 1: Obtaining various kenaf seeds and evaluating the characteristics of the seeds
사용된 케나프 종자는 2020년 전남 순천지역에서 재배된 '장대' 품종에서 채종한 종자와 외국산 8종 케나프 종자로 각각의 정보는 표 1 및 도 1에 나타내었다. 외국산 품종 중, 홍마는 중국산 홍마 74-3 종자를 ㈜케나프코리아에서 구입하여 사용하였으며, 그외 종자 7종(IT 181215 ~ IT 236176)은 국립농업과학원의 농업생명자원 분양 프로그램 지원으로 확보하였다(DT-22001). 표 1에 나타낸 바와 같이, 종자들의 크기는 0.48~0.53 cm로 유의성 있는 차이(p<0.05)가 없었으나, 백중립 무게는 종자별로 차이가 나타났다. 가장 무거운 종자는 IT 207886 중국산 종자였으며, 가장 가벼운 종자는 IT 181220 미국산 종자로 나타났다. 장대 품종의 케나프 종자는 2.72g/100 seeds로 쿠바산, 프랑스산 종자와 유사하였다. 종자의 무게는 구성성분 및 충실도를 반영하나, 종자 발아율과는 상관관계가 인정되지 않았다. 따라서, 케나프 품종별 종자 무게 차이는 종자 구성 성분의 차이, 재배 및 수확시기의 차이 및 저장기간의 차이 등 복합적인 요인에 의해 나타나는 특성으로 이해된다The kenaf seeds used were seeds harvested from the 'Jangdae' variety grown in the Suncheon region of Jeollanam-do in 2020 and 8 types of foreign kenaf seeds, and the information for each is shown in Table 1 and Figure 1. Among foreign varieties, Hongma used Chinese Hongma 74-3 seeds purchased from Kenaf Korea, and seven other types of seeds (IT 181215 ~ IT 236176) were secured through the support of the National Institute of Agricultural Science's agricultural bioresource distribution program (DT) -22001). As shown in Table 1, the size of the seeds ranged from 0.48 to 0.53 cm, with no significant difference (p<0.05), but the white neutral weight differed depending on the seed. The heaviest seed was IT 207886 from China, and the lightest seed was IT 181220 from the United States. Kenaf seeds of the pole variety were 2.72g/100 seeds, which was similar to seeds from Cuba and France. The weight of the seed reflects its composition and fidelity, but no correlation was recognized with the seed germination rate. Therefore, the difference in seed weight between kenaf varieties is understood to be a characteristic caused by complex factors such as differences in seed composition, differences in cultivation and harvest times, and differences in storage period.
[표 1] 다양한 케나프 품종별 종자의 특성 [Table 1] Seed characteristics of various kenaf varieties
실시예 2: 다양한 케나프 종자 추출 제조 및 이의 성분 분석 Example 2: Preparation of various kenaf seed extracts and analysis of their components
확보된 케나프 종자는 이물질을 제거한 후 세절하여 추출에 사용하였으며, 케나프 종자 시료에 각각 20배의 95% ethanol (Daejung Chemicals & Metals Co., Ltd. Korea)을 가한 후 상온에서 2일 동안 침지하여 추출하고, 추출액은 filter paper (Whatsman No. 2, GE healthcare UK limited, UK)로 거른 후 감압 농축(Eyela Rotary evaporator N-1110S, Tokyo Rikakikai Co., Ltd. Japan)후 동결건조하였다. 종자들의 추출 수율은 9~11%로 나타났으며, 종자 추출물의 성분 분석 결과는 표 2에 나타내었다. 성분 분석으로 총 폴리페놀, 총 플라보노이드, 총당 및 환원당 함량을 측정하였다. 총 폴리페놀 함량은 추출 검액 400μl에 50μl의 Folin-ciocalteau, 100μl의 Na2CO3 포화용액을 넣고 실온에서 1시간 방치한 후 725nm에서 흡광도를 측정하였다. 표준시약으로는 tannic acid를 사용하였다. 총 플라보노이드 함량은 각각의 시료를 18시간 메탄올 교반 추출하고, 여과한 추출 검액 400μl에 90% diethylene glycol 4ml를 첨가하고, 다시 1N NaOH 40μl를 넣고 37℃에서 1시간 반응 후 420nm에서 흡광도를 측정하였다. 표준시약으로는 rutin을 사용하였다. 환원당은 DNS법으로, 총당은 phenol-sulfuric acid법을 이용하여 정량하였다. The secured kenaf seeds were cut into pieces after removing foreign substances and used for extraction. Twenty times more 95% ethanol (Daejung Chemicals & Metals Co., Ltd. Korea) was added to each kenaf seed sample, and then soaked at room temperature for 2 days. The extract was filtered through filter paper (Whatsman No. 2, GE healthcare UK limited, UK), concentrated under reduced pressure (Eyela Rotary evaporator N-1110S, Tokyo Rikakikai Co., Ltd. Japan), and then freeze-dried. The extraction yield of the seeds was found to be 9-11%, and the results of component analysis of the seed extract are shown in Table 2. Total polyphenol, total flavonoid, total sugar, and reducing sugar content were measured through component analysis. The total polyphenol content was measured by adding 50 μl of Folin-ciocalteau and 100 μl of Na 2 CO 3 saturated solution to 400 μl of the extraction sample solution, leaving it at room temperature for 1 hour, and measuring the absorbance at 725 nm. Tannic acid was used as a standard reagent. To determine the total flavonoid content, each sample was extracted with methanol stirring for 18 hours, 4ml of 90% diethylene glycol was added to 400μl of the filtered extraction solution, 40μl of 1N NaOH was added again, and the absorbance was measured at 420nm after reacting for 1 hour at 37°C. Rutin was used as a standard reagent. Reducing sugars were quantified using the DNS method, and total sugars were quantified using the phenol-sulfuric acid method.
[표 2] 다양한 케나프 종자 추출물의 성분 분석 비교[Table 2] Comparison of component analysis of various kenaf seed extracts
표 2에 나타낸 바와 같이, 총 폴리페놀 함량 분석 결과 장대 품종 케나프 종자를 제외한 외국산 종자는 모두 5.9~8.7 mg/g를 포함하여 유의성 있는 차이가 나타나지 않았으나, 장대 품종의 케나프 종자 추출물에서는 14.4 mg/g으로 큰 차이가 나타났다(p<0.05). 총 플라보노이드 함량 분석에서도 장대 품종의 케나프 종자 추출물은 5.3 mg/g을 나타내어 여타의 외국산 품종의 종자에서 나타나는 0.7~1.5 mg/g과 큰 차이가 나타났다. 적색을 나타내는 홍마 종자의 경우 총 플라보노이드 함량은 4.8 mg/g으로 여타의 외국산 종자와는 차별화되었다. 한편, 총당 함량 분석 결과, IT 207884 (프랑스산), IT 181220 (미국산) 종자에서 각각 645.4 및 477.8 mg/g을 나타내어 다른 품종 종자와 차별화되었으며, 환원당 함량의 경우 중국산 홍마 품종의 종자 추출물이 여타의 종자와 차별화되는 114.3 mg/g의 높은 함량을 보였다. 따라서 국내 채종 가능한 장대 품종의 종자는 다른 종자들보다 상대적으로 높은 폴리페놀 및 플라보노이드 함량을 나타내어 우수한 생리 활성을 나타내리라 예상되었다.As shown in Table 2, the total polyphenol content analysis showed no significant difference, including 5.9 to 8.7 mg/g in all foreign seeds except for the long-growing kenaf seeds, but 14.4 mg in the long-growing kenaf seed extract. There was a significant difference with /g (p<0.05). Analysis of the total flavonoid content also showed that the kenaf seed extract of the Pole cultivar showed 5.3 mg/g, which was significantly different from the 0.7 to 1.5 mg/g found in the seeds of other foreign varieties. In the case of red hemp seeds, the total flavonoid content was 4.8 mg/g, which was different from other foreign seeds. Meanwhile, as a result of analyzing the total sugar content, seeds of IT 207884 (from France) and IT 181220 (from the United States) showed 645.4 and 477.8 mg/g, respectively, which differentiated them from other types of seeds. In terms of reducing sugar content, the seed extract of the Chinese red hemp variety was higher than other seeds. It showed a high content of 114.3 mg/g, differentiating it from seeds. Therefore, it was expected that the seeds of the Korean longifolia cultivar that can be grown domestically would exhibit relatively higher polyphenol and flavonoid contents than other seeds and thus exhibit excellent physiological activity.
실시예 3: 다양한 케나프 종자 추출물의 항균 활성 평가 Example 3: Evaluation of antibacterial activity of various kenaf seed extracts
실시예 2에서 얻어진, 다양한 케나프 종자 추출물의 항균활성을 평가하였으며, 그 결과를 표 3에 나타내었다. 평가 세균으로는 그람 음성균으로 Escherichia coli KCTC 1682, Proteus vulgaris KCTC 2433, Pseudomonas aeruginosa KACC 10186, Salmonella typhimurium KCTC 1926을 사용하였고, 그람 양성균으로는 Staphylococcus aureus KCTC 1916, Staphylococcus epidermidis ATCC 12228, Listeria monocytogenes KACC 10550, Bacillus subtilis KCTC 1924를 사용하였다. 한편, 항진균 활성 평가를 위해서는 Saccharomyces cerevisiae IF0 0233 및 캔디다증 진균감염증 원인균 Candida albicans KCTC 1940을 사용하였다. The antibacterial activity of various kenaf seed extracts obtained in Example 2 was evaluated, and the results are shown in Table 3. Escherichia coli KCTC 1682, Proteus vulgaris KCTC 2433, Pseudomonas aeruginosa KACC 10186, and Salmonella typhimurium KCTC 1926 were used as gram-negative bacteria, and Staphylococcus aureus KCTC 1916, Staphylococcus epidermidis ATCC 12228, and Listeria monocytogenes were used as gram-positive bacteria. genes KACC 10550, Bacillus subtilis KCTC 1924 was used. Meanwhile, to evaluate antifungal activity , Saccharomyces cerevisiae IF0 0233 and Candida albicans KCTC 1940, the causative agent of candidiasis fungal infection, were used.
먼저, 항세균 활성 평가의 경우, Nutrient broth(Difco Co., USA)에 각각의 세균을 접종하여 37℃에서 24시간 동안 배양한 후, 각 균주를 O.D.600 0.1로 조정하여 Nutrient agar(Difco Co., USA) 배지를 포함하는 멸균 petri dish(9015mm, 녹십자, 한국)에 100μl씩 도말하고, 각각의 시료 5μl를 멸균 disc-paper(지름 6.5mm, Whatsman No. 2)에 가하여, 37℃에서 24시간 동안 배양하였으며, 진균의 경우에는 Sabouraud dextrose(Difco Co. USA)를 이용하여 동일한 방법으로 30℃에서 24시간 동안 배양 후, 생육저지환의 크기를 측정하여 항균활성을 평가하였다. 대조구로는 항세균제인 엠피실린(ampicillin)과 항진균제인 마이코나졸(miconazole, Sigma Co., USA)을 각각 1g/disc 농도로 사용하였으며, 생육저지환의 크기는 육안으로 생육이 나타나지 않는 부분의 지름을 mm 단위로 측정하였고, 3회 이상 평가 후 대표 결과로 나타내었다. First, in the case of antibacterial activity evaluation, each bacteria was inoculated into Nutrient broth (Difco Co., USA) and cultured at 37°C for 24 hours, then each strain was incubated on Nutrient agar (Difco Co.) with the OD600 adjusted to 0.1. , USA), 100 μl of each sample was spread on a sterilized petri dish (9015 mm, Green Cross, Korea) containing medium, and 5 μl of each sample was added to sterile disc-paper (diameter 6.5 mm, Whatsman No. 2) and incubated at 37°C for 24 hours. In the case of fungi, the antibacterial activity was evaluated by measuring the size of growth-inhibiting rings after culturing at 30°C for 24 hours using the same method using Sabouraud dextrose (Difco Co. USA). As controls, the antibacterial agent ampicillin and the antifungal agent miconazole (Sigma Co., USA) were used at a concentration of 1g/disc each, and the size of the growth-inhibiting ring was calculated by measuring the diameter of the area where growth was not visible to the naked eye. Measurements were made in mm and presented as representative results after evaluation three or more times.
[표 3] 다양한 케나프 종자 추출물의 항균 활성 [Table 3] Antibacterial activity of various kenaf seed extracts
상기 표 3에 나타낸 바와 같이, 먼저 항세균 활성대조구로 사용된 엠피실린(1g/disc)의 경우 그람 양성 및 그람 음성 세균에 대해 11.0~35.0mm의 생육 억제환을 나타내어 강력한 항세균 활성을 확인하였으며, 항진균제인 마이코나졸(1g/disc)의 경우 C. albicans 및 S. cerevisiae에 대해 각각 14~15mm의 생육억제환을 나타내었다. 장대 품종의 케나프 종자 추출물을 제외한 다른 케나프 품종의 종자 추출물은 시험균 모두에 대해 매우 약한 항균력을 나타내었으며, 장대 품종의 케나프 종자 추출물은 L. monocytogenes, S. epidermidis, S. aureus 및 B. subtilis의 그람 양성균에 대해서 14~21.5mm의 생육억제환을 나타내어 강력한 항세균 활성을 보였으며, 또한 E. coli 및 P. vulgaris의 일부 그람 음성균에 대해 8~9mm의 생육억제환을 나타내었다. 특히, 장대 품종의 케나프 종자 추출물은 여타의 케나프 품종의 종자 추출물에서 나타나지 않은 S. cerevisiae 및 C. albicans에 대한 우수한 항진균 활성도 나타내었다. 이러한 결과는 장대 품종의 케나프 종자 추출물을 이용한 광범위 항세균 및 항진균제 개발이 가능함을 제시하고 있다. As shown in Table 3, ampicillin (1g/disc), which was first used as an antibacterial activity control, showed a growth inhibition ring of 11.0 to 35.0 mm for Gram-positive and Gram-negative bacteria, confirming strong antibacterial activity. , the antifungal agent miconazole (1g/disc) showed growth inhibition rings of 14 to 15 mm for C. albicans and S. cerevisiae , respectively. Seed extracts of other kenaf varieties, except for the kenaf seed extract of the long variety kenaf, showed very weak antibacterial activity against all test bacteria, and kenaf seed extracts of the long variety kenaf showed very weak antibacterial activity against L. monocytogenes , S. epidermidis , S. aureus , and B. It showed strong antibacterial activity by showing a growth inhibition ring of 14 to 21.5 mm against Gram - positive bacteria of . In particular, the kenaf seed extract of the pole variety also showed excellent antifungal activity against S. cerevisiae and C. albicans, which was not shown in the seed extracts of other kenaf varieties. These results suggest that it is possible to develop a broad-spectrum antibacterial and antifungal agent using kenaf seed extract of the pole variety.
실시예 4: 장대 품종의 케나프 종자 추출물의 산 및 열 안정성 평가 Example 4: Evaluation of acid and heat stability of kenaf seed extract of Pole cultivars
상기 실시예 2에서 얻은 장대 품종의 케나프 종자 추출물을 대상으로 항균 활성에 대한 열 안정성 및 산 안정성을 확인하였다. 상기 시료들은 100℃에서 1시간 열 처리, pH 2(0.01M HCl)에서 1시간 처리시 Staphylococccus aureus, P. vulgaris 및 C. albicans에 대한 항균 활성의 심각한 감소가 나타나지 않아 장대 품종의 케나프 종자 추출물은 높은 열 및 산 안정성을 나타내었다. 따라서, 상기의 장대 품종의 케나프 종자 추출물은 다양한 식품가공 공정하에서도 우수한 항균 활성을 유지할 것으로 예상된다.The heat stability and acid stability for antibacterial activity were confirmed for the kenaf seed extract of the Pole cultivar obtained in Example 2. The samples showed no significant decrease in antibacterial activity against Staphylococccus aureus , P. vulgaris , and C. albicans when heat-treated at 100°C for 1 hour and treated at pH 2 (0.01M HCl) for 1 hour, showing that the kenaf seed extract of the long-livers variety showed high thermal and acid stability. Therefore, the kenaf seed extract of the above-mentioned plant species is expected to maintain excellent antibacterial activity even under various food processing processes.
[연구개발과제][R&D tasks]
주관기관: 농업회사법인 (주)헴프앤알바이오Host organization: Hemp & R Bio Co., Ltd., an agricultural corporation
연구기관: 안동대학교 산학협력단Research organization: Andong University Industry-Academic Cooperation Foundation
연구과제명: 케나프 고부가가치화 및 이의 특허출원 지원 연구용역Research project name: High value-added kenaf and research service to support its patent application
기여율: 100%Contribution rate: 100%
연구기간: 2021. 10. 01. ~ 2021. 12. 31.Research period: 2021. 10. 01. ~ 2021. 12. 31.
연구수행기관: 안동대학교 식품영양학과Research institution: Department of Food and Nutrition, Andong University
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220031067A KR102677601B1 (en) | 2022-03-11 | 2022-03-11 | Antimicrobial composition comprising the kenaf seed extract of jang-dae cultivar |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220031067A KR102677601B1 (en) | 2022-03-11 | 2022-03-11 | Antimicrobial composition comprising the kenaf seed extract of jang-dae cultivar |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20230133724A KR20230133724A (en) | 2023-09-19 |
KR102677601B1 true KR102677601B1 (en) | 2024-06-25 |
Family
ID=88196697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220031067A KR102677601B1 (en) | 2022-03-11 | 2022-03-11 | Antimicrobial composition comprising the kenaf seed extract of jang-dae cultivar |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102677601B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100815476B1 (en) | 2006-04-27 | 2008-03-20 | 강원대학교산학협력단 | Kenaf extract and novel kaempferol compound isolated them, and its use |
KR102188643B1 (en) | 2019-02-22 | 2020-12-09 | 박대현 | Method of manufacture of probiotics, a herbivorous feed additive, with a new breed of jangdae of Kenaf as the main ingredient |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102260228B1 (en) * | 2019-07-29 | 2021-06-03 | (주)케나프 | Antibacterial composition containing extract of kenaf seed as effective component |
-
2022
- 2022-03-11 KR KR1020220031067A patent/KR102677601B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100815476B1 (en) | 2006-04-27 | 2008-03-20 | 강원대학교산학협력단 | Kenaf extract and novel kaempferol compound isolated them, and its use |
KR100835710B1 (en) | 2006-04-27 | 2008-06-09 | 강원대학교산학협력단 | Kenaf extract and novel kaempferol compound isolated them, and its use for food |
KR102188643B1 (en) | 2019-02-22 | 2020-12-09 | 박대현 | Method of manufacture of probiotics, a herbivorous feed additive, with a new breed of jangdae of Kenaf as the main ingredient |
Non-Patent Citations (1)
Title |
---|
품종보호권 제4560호, 한국원자력연구원 첨단방사선연구소 (2013.)* |
Also Published As
Publication number | Publication date |
---|---|
KR20230133724A (en) | 2023-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20200003993A (en) | Antimicrobial composition comprising the leaf extract of polygonium ticnctorium and use thereof | |
KR102243591B1 (en) | Antimicrobial composition comprising the extract of rodgersia podophylla | |
KR101791549B1 (en) | An antibacterial composition comprising the pachyrhizus erosus root bark extract as an effective component | |
KR101715622B1 (en) | Antimicrobial composition comprising the extraction of suaeda spp as an effective component | |
KR102086166B1 (en) | Antimicrobial composition comprising the extracts of rambutan peel | |
KR101602552B1 (en) | Antimicrobial composition comprising the extract of cornus officinalis | |
KR102254420B1 (en) | Antimicrobial composition comprising the fermentation extract of medicinal or edible natural products | |
KR101976201B1 (en) | Antimicrobial composition comprising the sprout extract of zingiber officinale | |
KR102254424B1 (en) | Antimicrobial composition comprising the extract of sageretia thea | |
KR101911847B1 (en) | Antimicrobial composition comprising organic solvent fractions of arctium lappa root extracts as an effective component | |
KR102677601B1 (en) | Antimicrobial composition comprising the kenaf seed extract of jang-dae cultivar | |
KR102481102B1 (en) | Antibacterial composition containing starfish extract and cinnamon extract as active ingredients | |
KR20220094308A (en) | Pharmaceutical composition for preventing or treating infectious symptoms by pathogenic microorganism comprising Cichorium intybus extract as an active ingredient | |
KR102534868B1 (en) | Antimicrobial composition comprising the extract from coccon of protaetia brevitarsis | |
KR102254425B1 (en) | Antimicrobial composition comprising the extract of immature fruit extract of magnolia denudata | |
KR102669103B1 (en) | Antimicrobial composition comprising the micro scaled powder of bast fiber of cannabis sativa l. | |
KR102287389B1 (en) | Antimicrobial composition comprising the extract of flower bud of panax ginseng c. a. meyer | |
KR102287391B1 (en) | Antimicrobial composition comprising the extract of moringa root | |
KR102131454B1 (en) | Antimicrobial composition comprising the extract of yunnongchamssal | |
KR102572181B1 (en) | Antimicrobial composition comprising the extract from wasp | |
KR20200058353A (en) | Antimicrobial composition comprising the hexane and butanol fractions of teleogryllus emma extract | |
KR20240021683A (en) | Antimicrobial composition comprising the extracts of pollen of cannabis sativa l. | |
KR102428964B1 (en) | Antimicrobial composition comprising the extracts of hermetia illucens | |
KR20200113919A (en) | Antimicrobial composition comprising the extract of loranthus yadoriki | |
KR20240048145A (en) | Antimicrobial composition comprising the extract of songhwa mushroom fruiting body |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |